Endocrine therapies that target estrogen action (antiestrogens and aromatase inhibitors) are widely used and successful breast cancer therapies, but many women treated with these therapies will relapse with endocrine-resistant disease [67]. Here, CYP19A1 is linked to breast carcinoma.